DiaMedica Therapeutics Inc.
DMAC
$3.53
-$0.01-0.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.58% | 11.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.32% | 22.08% | |||
| Operating Income | -22.32% | -22.08% | |||
| Income Before Tax | -25.91% | -22.59% | |||
| Income Tax Expenses | 28.57% | 0.00% | |||
| Earnings from Continuing Operations | -25.92% | -22.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.92% | -22.56% | |||
| EBIT | -22.32% | -22.08% | |||
| EBITDA | -22.33% | -22.12% | |||
| EPS Basic | -25.75% | -9.14% | |||
| Normalized Basic EPS | -25.76% | -9.18% | |||
| EPS Diluted | -25.75% | -9.14% | |||
| Normalized Diluted EPS | -25.76% | -9.18% | |||
| Average Basic Shares Outstanding | 0.13% | 12.30% | |||
| Average Diluted Shares Outstanding | 0.13% | 12.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||